Dr. Tsu-An Hsu is the CEO and CSO of Anbogen Therapeutics. He has blended R&D experiences in biopharma companies and research institutes, e.g. Human Genome Sciences, Merck & Co and National Health Research Institutes. He identified existing drugs for inhibition of SARS-CoV during the SARS outbreak in 2003.